MLEC

Company Overview — What Does Moolec Science SA Do?

Moolec Science is a science-based ingredient company focused on producing animal proteins in plants through Molecular Farming. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybeans and peas. Moolec Science SA (MLEC) is classified as a micro-cap stock in the Financials sector, specifically within the Trading industry. The company is led by CEO Gastón Paladini and employs approximately 4 people. With a market capitalization of $5M, MLEC is one of the notable companies in the Financials sector.

Moolec Science SA (MLEC) Stock Rating — Reduce (April 2026)

As of April 2026, Moolec Science SA receives a Reduce rating with a composite score of 34.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MLEC ranks #3,267 out of 4,446 stocks in our coverage universe. Within the Financials sector, Moolec Science SA ranks #757 of 891 stocks, placing it in the lower half of its Financials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MLEC Stock Price and 52-Week Range

Moolec Science SA (MLEC) currently trades at $8.37. The stock gained $0.26 (3.2%) in the most recent trading session. The 52-week high for MLEC is $23.22, which means the stock is currently trading -64.0% from its annual peak. The 52-week low is $0.21, putting the stock 3980.9% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is MLEC Overvalued or Undervalued? — Valuation Analysis

Moolec Science SA (MLEC) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 0.01x, compared to 0.90x for the average Financials stock.

At current multiples, Moolec Science SA trades at a premium to most Financials peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Moolec Science SA Profitability — ROE, Margins, and Quality Score

Moolec Science SA (MLEC) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -345.1% versus the sector average of 1.2%.

On a margin basis, Moolec Science SA reports gross margins of 26.2%. The operating margin is -64.7% (sector: 21.8%). Net profit margin stands at -53.2%, versus 17.7% for the average Financials stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MLEC Debt, Balance Sheet, and Financial Health

Balance sheet data for MLEC is evaluated through our stability factor. Total debt on the balance sheet is $247M. Cash and equivalents stand at $767,919.

MLEC has a beta of 2.82, meaning it is more volatile than the broader market — a $10,000 investment in MLEC would be expected to move 182.5% more than the S&P 500 on any given day. The stability factor score for Moolec Science SA is 6/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Moolec Science SA Revenue and Earnings History — Quarterly Trend

In TTM 2026, Moolec Science SA reported revenue of $332M. Net income for the quarter was $-177M. Gross margin was 26.2%. Operating income came in at $-215M.

In FY 2025, Moolec Science SA reported revenue of $332M. Net income for the quarter was $-177M. Gross margin was 26.2%. Revenue grew -28.5% year-over-year compared to FY 2024. Operating income came in at $-215M.

In FY 2024, Moolec Science SA reported revenue of $464M. Net income for the quarter was $-29M. Gross margin was 31.7%. Revenue grew 11.4% year-over-year compared to FY 2023. Operating income came in at $22M.

In FY 2023, Moolec Science SA reported revenue of $417M. Net income for the quarter was $53M. Gross margin was 35.4%. Operating income came in at $114M.

Over the past 5 quarters, Moolec Science SA has demonstrated a growth trajectory, with revenue expanding from $0 to $332M. Investors analyzing MLEC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MLEC Dividend Yield and Income Analysis

Moolec Science SA (MLEC) does not currently pay a dividend. This is common among smaller companies in the Trading industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Financials dividend stocks may want to explore other Financials stocks or use the stock screener to filter by dividend yield.

MLEC Momentum and Technical Analysis Profile

Moolec Science SA (MLEC) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 13/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 32/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

MLEC vs Competitors — Financials Sector Ranking and Peer Comparison

Within the Financials sector, Moolec Science SA (MLEC) ranks #757 out of 891 stocks based on the Blank Capital composite score. This places MLEC in the lower half of all Financials stocks in our coverage universe. Key competitors and sector peers include WHITE MOUNTAINS INSURANCE GROUP LTD (WTM) with a score of 62.9/100, OPPENHEIMER HOLDINGS INC (OPY) with a score of 62.6/100, Enact Holdings, Inc. (ACT) with a score of 61.6/100, International General Insurance Holdings Ltd. (IGIC) with a score of 61.3/100, and PARKE BANCORP, INC. (PKBK) with a score of 60.4/100.

Comparing MLEC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MLEC vs S&P 500 (SPY) comparison to assess how Moolec Science SA stacks up against the broader market across all factor dimensions.

MLEC Next Earnings Date

No upcoming earnings date has been announced for Moolec Science SA (MLEC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MLEC? — Investment Thesis Summary

The quantitative profile for Moolec Science SA suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 78/100, suggesting the trend favors buyers. High volatility (stability score 6/100) increases portfolio risk.

In summary, Moolec Science SA (MLEC) earns a Reduce rating with a composite score of 34.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MLEC stock.

Related Resources for MLEC Investors

Explore more research and tools: MLEC vs S&P 500 comparison, top Financials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MLEC head-to-head with peers: MLEC vs WTM, MLEC vs OPY, MLEC vs ACT.